Drug-resistant infections have become a public health crisis. We are at the precipice of the post-antibiotic era, where routine surgeries and standard in-patient care present unacceptable risk. Octagon has developed a novel approach to antibiotic discovery, which utilizes bacterial metabolism as a therapeutic target. Our lead development candidates, which show no effect in standard industry screens, have been shown safe and highly effective in animal models. This is a critical medical need.

2017 Boston Finalist